VAXCYTE, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
VAXCYTE, INC. (PCVX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $5.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-05
- VAXCYTE, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $2.92M, a 38.58% increase year-over-year.
- VAXCYTE, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $2.91M, a 51.56% increase year-over-year.
- VAXCYTE, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $2.30M, a 19.89% increase year-over-year.
- VAXCYTE, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $2.13M, a 21.09% decline year-over-year.
- VAXCYTE, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $8.46M, a 4.28% decline from fiscal 2024.
- VAXCYTE, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $8.84M, a 26.04% increase from fiscal 2023.
- VAXCYTE, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $7.01M, a 5.98% increase from fiscal 2022.
- VAXCYTE, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $6.62M, a 299.46% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.83M 10-Q · filed 2026-08-05 | $8.13M derived: sum of 3 quarters · filed 2026-08-05 | $10.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.91M 10-Q · filed 2026-05-06 | $5.21M derived: sum of 2 quarters · filed 2026-05-06 | $7.34M derived: sum of 3 quarters · filed 2026-05-06 | $9.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.44M derived: sum of 2 quarters · filed 2026-02-24 | $6.55M derived: sum of 3 quarters · filed 2026-08-05 | $8.46M 10-K · filed 2026-02-24 |
| 2025-09-30 | $2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $4.24M derived: sum of 2 quarters · filed 2026-08-05 | $6.16M 10-Q · filed 2025-11-04 | $8.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.03M 10-Q · filed 2026-08-05 | $5.95M derived: sum of 3 quarters · filed 2026-08-05 | $8.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.92M 10-Q · filed 2026-05-06 | $3.84M derived: sum of 2 quarters · filed 2026-05-06 | $6.54M derived: sum of 3 quarters · filed 2026-05-06 | $8.67M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.62M derived: sum of 2 quarters · filed 2026-02-24 | $6.75M derived: sum of 3 quarters · filed 2026-02-24 | $8.84M 10-K · filed 2026-02-24 |
| 2024-09-30 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $4.83M derived: sum of 2 quarters · filed 2025-11-04 | $6.92M 10-Q · filed 2025-11-04 | $8.98M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $4.22M 10-Q · filed 2025-08-06 | $6.28M derived: sum of 3 quarters · filed 2026-02-24 | $7.95M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $2.09M 10-Q · filed 2025-05-07 | $4.15M derived: sum of 2 quarters · filed 2026-02-24 | $5.83M derived: sum of 3 quarters · filed 2026-02-24 | $7.48M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.73M derived: sum of 2 quarters · filed 2026-02-24 | $5.38M derived: sum of 3 quarters · filed 2026-02-24 | $7.01M 10-K · filed 2026-02-24 |
| 2023-09-30 | $1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $3.33M derived: sum of 2 quarters · filed 2024-11-05 | $4.96M 10-Q · filed 2024-11-05 | $6.55M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $3.28M 10-Q · filed 2024-08-06 | $4.88M derived: sum of 3 quarters · filed 2025-02-25 | $6.55M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $1.63M 10-Q · filed 2024-05-08 | $3.23M derived: sum of 2 quarters · filed 2025-02-25 | $4.90M derived: sum of 3 quarters · filed 2025-02-25 | $6.46M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $3.27M derived: sum of 2 quarters · filed 2025-02-25 | $4.83M derived: sum of 3 quarters · filed 2025-02-25 | $6.62M 10-K · filed 2025-02-25 |
| 2022-09-30 | $1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $3.23M derived: sum of 2 quarters · filed 2023-11-06 | $5.02M 10-Q · filed 2023-11-06 | $5.77M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.35M 10-Q · filed 2023-08-08 | $4.10M derived: sum of 3 quarters · filed 2024-02-27 | $4.44M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $1.79M 10-Q · filed 2023-05-08 | $2.53M derived: sum of 2 quarters · filed 2024-02-27 | $2.88M derived: sum of 3 quarters · filed 2024-02-27 | $3.26M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $747.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.09M derived: sum of 2 quarters · filed 2024-02-27 | $1.48M derived: sum of 3 quarters · filed 2024-02-27 | $1.66M 10-K · filed 2024-02-27 |
| 2021-09-30 | $346.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $730.00K derived: sum of 2 quarters · filed 2022-11-07 | $910.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $384.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $564.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $180.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |